# ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

> **NCT00436852** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 92 (actual)

## Conditions studied

- Disseminated Neuroblastoma
- Recurrent Neuroblastoma

## Interventions

- **DRUG:** ABT-751
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00436852
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-09-01
- **Final completion:** 2015-03-30
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2019-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436852, "ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00436852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*